rs3731204

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_058195.4(CDKN2A):​c.193+6554A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.113 in 152,194 control chromosomes in the GnomAD database, including 1,114 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.11 ( 1114 hom., cov: 32)

Consequence

CDKN2A
NM_058195.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.552

Publications

13 publications found
Variant links:
Genes affected
CDKN2A (HGNC:1787): (cyclin dependent kinase inhibitor 2A) This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
CDKN2A Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • melanoma-pancreatic cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • familial atypical multiple mole melanoma syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • melanoma and neural system tumor syndrome
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.134 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDKN2ANM_058195.4 linkc.193+6554A>G intron_variant Intron 1 of 2 ENST00000579755.2 NP_478102.2 Q8N726-1
LOC124902130XR_007061436.1 linkn.5039A>G non_coding_transcript_exon_variant Exon 2 of 2
CDKN2ANM_001363763.2 linkc.-4+7236A>G intron_variant Intron 1 of 2 NP_001350692.1
CDKN2AXM_047422597.1 linkc.-4+6962A>G intron_variant Intron 1 of 2 XP_047278553.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDKN2AENST00000579755.2 linkc.193+6554A>G intron_variant Intron 1 of 2 1 NM_058195.4 ENSP00000462950.1 Q8N726-1

Frequencies

GnomAD3 genomes
AF:
0.113
AC:
17128
AN:
152076
Hom.:
1113
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0949
Gnomad AMI
AF:
0.277
Gnomad AMR
AF:
0.105
Gnomad ASJ
AF:
0.143
Gnomad EAS
AF:
0.000769
Gnomad SAS
AF:
0.0349
Gnomad FIN
AF:
0.0999
Gnomad MID
AF:
0.130
Gnomad NFE
AF:
0.137
Gnomad OTH
AF:
0.136
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.113
AC:
17141
AN:
152194
Hom.:
1114
Cov.:
32
AF XY:
0.108
AC XY:
8051
AN XY:
74408
show subpopulations
African (AFR)
AF:
0.0948
AC:
3937
AN:
41538
American (AMR)
AF:
0.105
AC:
1601
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
0.143
AC:
494
AN:
3466
East Asian (EAS)
AF:
0.000771
AC:
4
AN:
5188
South Asian (SAS)
AF:
0.0346
AC:
167
AN:
4832
European-Finnish (FIN)
AF:
0.0999
AC:
1058
AN:
10590
Middle Eastern (MID)
AF:
0.139
AC:
41
AN:
294
European-Non Finnish (NFE)
AF:
0.137
AC:
9291
AN:
67976
Other (OTH)
AF:
0.140
AC:
295
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
776
1552
2327
3103
3879
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
186
372
558
744
930
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.124
Hom.:
153
Bravo
AF:
0.116
Asia WGS
AF:
0.0470
AC:
164
AN:
3476

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.87
CADD
Benign
0.50
DANN
Benign
0.54
PhyloP100
-0.55
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs3731204; hg19: chr9-21987584; API